AR068066A1 - Derivados de tieno(3, 2-b)piridin-7-iloxi, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por inhibidores de la actividad de la proteina tirosina quinasa. - Google Patents
Derivados de tieno(3, 2-b)piridin-7-iloxi, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por inhibidores de la actividad de la proteina tirosina quinasa.Info
- Publication number
- AR068066A1 AR068066A1 ARP080103775A ARP080103775A AR068066A1 AR 068066 A1 AR068066 A1 AR 068066A1 AR P080103775 A ARP080103775 A AR P080103775A AR P080103775 A ARP080103775 A AR P080103775A AR 068066 A1 AR068066 A1 AR 068066A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- group
- aryl
- alkynyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 25
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000006537 (C6-C10)-aryl alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96867307P | 2007-08-29 | 2007-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068066A1 true AR068066A1 (es) | 2009-11-04 |
Family
ID=40386626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103775A AR068066A1 (es) | 2007-08-29 | 2008-08-29 | Derivados de tieno(3, 2-b)piridin-7-iloxi, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por inhibidores de la actividad de la proteina tirosina quinasa. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8404846B2 (https=) |
| EP (1) | EP2183254B1 (https=) |
| JP (1) | JP5656634B2 (https=) |
| KR (1) | KR101556269B1 (https=) |
| CN (3) | CN109970759A (https=) |
| AR (1) | AR068066A1 (https=) |
| AU (1) | AU2008293038B2 (https=) |
| BR (1) | BRPI0816064B8 (https=) |
| CA (1) | CA2697795C (https=) |
| DK (1) | DK2183254T3 (https=) |
| ES (1) | ES2635131T3 (https=) |
| IL (1) | IL204192A (https=) |
| MX (1) | MX2010002427A (https=) |
| MY (1) | MY156536A (https=) |
| PL (1) | PL2183254T3 (https=) |
| RU (1) | RU2495044C2 (https=) |
| TW (1) | TWI571468B (https=) |
| WO (1) | WO2009026717A1 (https=) |
| ZA (1) | ZA201001512B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0908573A2 (pt) * | 2008-03-05 | 2012-12-25 | Methylgene Inc | inibidores da atividade de proteÍna tirosina quinase |
| EP2340244A4 (en) * | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
| ES2578990T3 (es) * | 2009-03-21 | 2016-08-03 | Sunshine Lake Pharma Co., Ltd. | Derivados de amino éster, sales de los mismos y métodos de uso |
| IN2012DN02493A (https=) * | 2009-09-03 | 2015-08-28 | Allergan Inc | |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8455484B2 (en) * | 2010-04-16 | 2013-06-04 | Methylgene Inc. | Selected inhibitors of protein tyrosine kinase activity |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AU2011307306A1 (en) * | 2010-09-27 | 2013-05-02 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| CA2812750C (en) * | 2010-09-27 | 2020-10-06 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| EP2621483A1 (en) * | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| CN102827186A (zh) * | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス， インク． | 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤 |
| CN103626761B (zh) * | 2012-08-24 | 2015-07-29 | 上海医药工业研究院 | 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用 |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| EP3227276B1 (en) | 2014-12-02 | 2021-09-01 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| CN108530464B (zh) * | 2017-03-02 | 2020-10-27 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂 |
| AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| EP3762392B1 (en) * | 2018-03-08 | 2024-05-15 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| CN112566935B (zh) | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| CN109384799B (zh) * | 2018-11-12 | 2020-07-14 | 深圳海王医药科技研究院有限公司 | 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物 |
| CN112771053A (zh) | 2019-09-06 | 2021-05-07 | 伟迈可生物有限公司 | 基于生物标志物的治疗组合物 |
| EP4027999B1 (en) * | 2019-09-10 | 2026-03-04 | Mirati Therapeutics, Inc. | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof |
| US20230022859A1 (en) * | 2019-11-21 | 2023-01-26 | Beigene, Ltd. | Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors |
| US20230094146A1 (en) * | 2020-01-07 | 2023-03-30 | Medshine Discovery Inc. | Deuterated thienopyridine compound |
| WO2022060831A1 (en) | 2020-09-17 | 2022-03-24 | Mirati Therapeutics, Inc. | Combination therapies |
| TW202302597A (zh) * | 2021-03-10 | 2023-01-16 | 美商米拉蒂醫療公司 | 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途 |
| WO2022240802A1 (en) | 2021-05-10 | 2022-11-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of sitravatinib salts and processes for preparation thereof |
| WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
| CN118846073B (zh) * | 2024-06-25 | 2026-01-30 | 深圳海王医药科技研究院有限公司 | 一种酪氨酸激酶抑制剂的新应用 |
| CN121281693B (zh) * | 2025-12-08 | 2026-04-03 | 中国石油大学(华东) | 一种构建稠油重组分平均分子结构的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019A (en) * | 1850-01-15 | Improvement in obstetrical supporters | ||
| US7000A (en) * | 1850-01-08 | Smut-machine | ||
| US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| EP1652847B1 (en) | 2001-04-27 | 2008-05-28 | Kirin Pharma Kabushiki Kaisha | Quinoline and quinazoline derivatives for the treatment of tumors |
| EP2258366B1 (en) | 2001-06-22 | 2013-04-03 | Kirin Pharma Kabushiki Kaisha | Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| JP2005511713A (ja) * | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
| UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| EP1719762B1 (en) | 2004-02-27 | 2012-06-27 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (1) |
| US8940896B2 (en) * | 2004-03-15 | 2015-01-27 | Ptc Therapeutics, Inc. | Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis |
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| KR101257343B1 (ko) * | 2004-07-30 | 2013-04-23 | 메틸진 인코포레이티드 | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 |
| AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| CN101796055B (zh) * | 2005-05-20 | 2013-09-04 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
| AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| HRP20130719T1 (en) | 2005-08-24 | 2013-09-30 | Eisai R&D Management Co., Ltd. | Novel pyridine derivative and pyrimidine derivative (3) |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| BRPI0708615A2 (pt) | 2006-03-07 | 2011-06-07 | Array Biopharma Inc | compostos de pirazol heterobicìclicos e métodos de uso |
| WO2007107005A1 (en) * | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
| JP2009539878A (ja) | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| WO2008049855A2 (en) | 2006-10-27 | 2008-05-02 | Glaxo Group Limited | 7-azaindole derivatives as c-met kinase inhibitors |
| US8455484B2 (en) * | 2010-04-16 | 2013-06-04 | Methylgene Inc. | Selected inhibitors of protein tyrosine kinase activity |
-
2008
- 2008-08-28 BR BRPI0816064A patent/BRPI0816064B8/pt active IP Right Grant
- 2008-08-28 MY MYPI2010000797A patent/MY156536A/en unknown
- 2008-08-28 KR KR1020107006866A patent/KR101556269B1/ko active Active
- 2008-08-28 AU AU2008293038A patent/AU2008293038B2/en active Active
- 2008-08-28 RU RU2010111729/04A patent/RU2495044C2/ru active
- 2008-08-28 WO PCT/CA2008/001538 patent/WO2009026717A1/en not_active Ceased
- 2008-08-28 MX MX2010002427A patent/MX2010002427A/es active IP Right Grant
- 2008-08-28 JP JP2010522149A patent/JP5656634B2/ja active Active
- 2008-08-28 CN CN201910332646.2A patent/CN109970759A/zh active Pending
- 2008-08-28 CN CN2008801139404A patent/CN101932586A/zh active Pending
- 2008-08-28 CA CA2697795A patent/CA2697795C/en active Active
- 2008-08-28 EP EP08800252.2A patent/EP2183254B1/en active Active
- 2008-08-28 ES ES08800252.2T patent/ES2635131T3/es active Active
- 2008-08-28 DK DK08800252.2T patent/DK2183254T3/en active
- 2008-08-28 CN CN201610143388.XA patent/CN105777776B/zh active Active
- 2008-08-28 PL PL08800252T patent/PL2183254T3/pl unknown
- 2008-08-29 US US12/200,939 patent/US8404846B2/en active Active
- 2008-08-29 AR ARP080103775A patent/AR068066A1/es active IP Right Grant
- 2008-08-29 TW TW097133329A patent/TWI571468B/zh active
-
2010
- 2010-02-25 IL IL204192A patent/IL204192A/en active IP Right Grant
- 2010-03-02 ZA ZA2010/01512A patent/ZA201001512B/en unknown
-
2011
- 2011-12-30 US US13/341,604 patent/US8389541B2/en active Active
-
2013
- 2013-02-14 US US13/767,506 patent/US8846927B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068066A1 (es) | Derivados de tieno(3, 2-b)piridin-7-iloxi, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por inhibidores de la actividad de la proteina tirosina quinasa. | |
| AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
| AR067413A1 (es) | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer | |
| BR9911590A (pt) | Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| HRP20150825T1 (hr) | Imidazo[1,2,-a]piridinski derivati kao inhibitori fgfr kinaze za uporabu u terapiji | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| DE60128343D1 (de) | Pyrimidine verbindungen | |
| ES2721268T3 (es) | Compuestos de pirazolo[1,5-a]pirimidina-5,7-diamina como inhibidores de CDK y su uso terapéutico | |
| AR069802A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| AR002746A1 (es) | Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos. | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
| DK1378510T3 (da) | Triazaspiro[5.5]undecan-derivater og lægemidler indeholdende disse som en aktiv bestanddel | |
| AR056886A1 (es) | Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer | |
| AR060903A1 (es) | Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp | |
| AR084637A1 (es) | Compuestos heterociclicos apropiados para el tratamiento de la dislipidemia | |
| AR077050A1 (es) | Derivados de bencimidazol e imidazo[4, 5-c]piridina, una composicion farmaceutica que los comprende y su uso para la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la via hedgehog | |
| PH12021550857A1 (en) | Compounds, compositions, and methods for modulating cdk9 activity | |
| HRP20201522T1 (hr) | Heteroaromatski nmda receptor modulatori i njihove uporabe | |
| CL2020003227A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak. | |
| AR010260A1 (es) | Compuestos derivados de 1-(2-metoxifenil)-4-(fenoxialquilen)-piperazina; composiciones farmaceuticas que los contienen; un proceso para la preparacionde dichos compuestos y composiciones farmaceuticas y uso de dicho compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |